Lei Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lei Huang has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Xiaodong Liao
Department of Histoembryology Genetics and Developmental Biology Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education Shanghai Key Laboratory of Reproductive Medicine Shanghai Jiao Tong University School of Medicine Shanghai 200025 China
10 shared publicationsHuayun Deng
Department of Histoembryology Genetics and Developmental Biology Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education Shanghai Key Laboratory of Reproductive Medicine Shanghai Jiao Tong University School of Medicine Shanghai 200025 China
5 shared publicationsQuanfu Li
Department of Histoembryology Genetics and Developmental Biology Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education Shanghai Key Laboratory of Reproductive Medicine Shanghai Jiao Tong University School of Medicine Shanghai 200025 China
5 shared publicationsWei Jin
Department of Histoembryology Genetics and Developmental Biology Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education Shanghai Key Laboratory of Reproductive Medicine Shanghai Jiao Tong University School of Medicine Shanghai 200025 China
5 shared publicationsZhi Pang
Department of Histoembryology, Genetics and Developmental Biology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Key Laboratory of Reproductive Medicine, Shanghai Jiao Tong University School of Medicine, Innovative research team of high-level local universities in Shanghai, Shanghai, P. R. China
5 shared publicationsJie Yang
4 shared publications
Latest Publications
- Open Access
MUC1 Protects Preimplantation Embryos In Vitro via Clearance of ROS by Triggering Mitophagy
Embryos being treated using assisted reproductive technology (ART) are unavoidably exposed to physical stressors, thus producing reactive oxygen species (ROS) which trigger mitophagy to support embryonic development. However, the mechanisms underlying the regulation of mitophagy in early embryonic development remain largely unexplored. Here, we found that Mucin 1 (MUC1) exhibited a uniform distribution in both mouse and human oocytes, and its expression peaked at the blastocyst stage. Further analysis revealed that Muc1 knockout impairs blastocyst formation in vitro. Correspondingly, Muc1 knockout led to the accumulation of mitochondrial reactive oxygen species (mtROS) and a reduction in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)/Parkinson protein 2 (PARK2/Parkin)-dependent mitophagy. Stimulation of mitophagy via low-dose carbonyl cyanide 3-chlorophenylhydrazone (CCCP) treatment rescued the blastocyst formation defect in Muc1-null embryos. Vitamin C supplementation effectively scavenged mtROS and restored developmental competence. Together, our findings establish that MUC1 safeguards early embryonic development by promoting mitophagy to decrease mtROS levels in vitro. Moreover, vitamin C could compensate for Muc1 deficiency by eliminating mtROS. This study not only identified a new function of MUC1 in protecting early embryonic development in vitro, but also revealed a novel mechanism of mitophagy regulation in early embryos, which has potential applications for ART.
Open AccessMUC1 Protects Preimplantation Embryos In Vitro via Clearance of ROS by Triggering Mitophagy
Embryos being treated using assisted reproductive technology (ART) are unavoidably exposed to physical stressors, thus producing reactive oxygen species (ROS) which trigger mitophagy to support embryonic development. However, the mechanisms underlying the regulation of mitophagy in early embryonic development remain largely unexplored. Here, we found that Mucin 1 (MUC1) exhibited a uniform distribution in both mouse and human oocytes, and its expression peaked at the blastocyst stage. Further analysis revealed that Muc1 knockout impairs blastocyst formation in vitro. Correspondingly, Muc1 knockout led to the accumulation of mitochondrial reactive oxygen species (mtROS) and a reduction in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)/Parkinson protein 2 (PARK2/Parkin)-dependent mitophagy. Stimulation of mitophagy via low-dose carbonyl cyanide 3-chlorophenylhydrazone (CCCP) treatment rescued the blastocyst formation defect in Muc1-null embryos. Vitamin C supplementation effectively scavenged mtROS and restored developmental competence. Together, our findings establish that MUC1 safeguards early embryonic development by promoting mitophagy to decrease mtROS levels in vitro. Moreover, vitamin C could compensate for Muc1 deficiency by eliminating mtROS. This study not only identified a new function of MUC1 in protecting early embryonic development in vitro, but also revealed a novel mechanism of mitophagy regulation in early embryos, which has potential applications for ART.
- Open Access
- 11 May 2025
- Published by Wiley in Advanced Science
- Vol. 12 (25) , e2503545
PP2A Promotes the Symmetric Division of MUC1‐Dominant Cancer Stem‐Like Cells in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is the most aggressive and lethal subtype of lung cancer. Cancer stem‐like cells (CSLCs) are primarily responsible for carcinogenesis, therapeutic resistance, and tumor recurrence. This study reported that high level of mucin1 (MUC1) is associated with poor patient survival in SCLC. MUC1 expression peaks during the G2/M phase and facilitates symmetric division and expansion of CSLCs. Mechanistically, the interaction of MUC1 and protein phosphatase 2A (PP2A) results in augmented PP2A activity, which leads to reduced phosphorylation of protein kinase C ζ (PKCζ), ultimately decreases phosphorylation of NUMB. Both pharmacological and genetic strategies demonstrate that targeted‐inhibition of the MUC1‐PP2A axis pointedly rescues phosphorylation of PKCζ and NUMB, thereby shifting CSLCs towards asymmetric division and represses CSLCs proliferation. Conversely, inhibitor of PKCζ suppresses phosphorylation of NUMB, promotes symmetric division and induces enrichment of CSLCs. Moreover, combination of etoposide and inhibitors of MUC1‐PP2A pathway efficiently constrains tumor growth in vitro and in vivo. Importantly, a negative correlation is observed between MUC1 and phosphorylation of PKCζ and NUMB in SCLC patients. Therefore, this study reveals a novel mechanism by which MUC1‐PP2A awakes CSLC expansion via switching symmetric division, suggesting a potential therapeutic strategy for MUC1‐positive SCLC.
- 11 May 2025
- Published by Wiley in Advanced Science
- Vol. 12 (25) , e2503545
Open AccessPP2A Promotes the Symmetric Division of MUC1‐Dominant Cancer Stem‐Like Cells in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is the most aggressive and lethal subtype of lung cancer. Cancer stem‐like cells (CSLCs) are primarily responsible for carcinogenesis, therapeutic resistance, and tumor recurrence. This study reported that high level of mucin1 (MUC1) is associated with poor patient survival in SCLC. MUC1 expression peaks during the G2/M phase and facilitates symmetric division and expansion of CSLCs. Mechanistically, the interaction of MUC1 and protein phosphatase 2A (PP2A) results in augmented PP2A activity, which leads to reduced phosphorylation of protein kinase C ζ (PKCζ), ultimately decreases phosphorylation of NUMB. Both pharmacological and genetic strategies demonstrate that targeted‐inhibition of the MUC1‐PP2A axis pointedly rescues phosphorylation of PKCζ and NUMB, thereby shifting CSLCs towards asymmetric division and represses CSLCs proliferation. Conversely, inhibitor of PKCζ suppresses phosphorylation of NUMB, promotes symmetric division and induces enrichment of CSLCs. Moreover, combination of etoposide and inhibitors of MUC1‐PP2A pathway efficiently constrains tumor growth in vitro and in vivo. Importantly, a negative correlation is observed between MUC1 and phosphorylation of PKCζ and NUMB in SCLC patients. Therefore, this study reveals a novel mechanism by which MUC1‐PP2A awakes CSLC expansion via switching symmetric division, suggesting a potential therapeutic strategy for MUC1‐positive SCLC.
- Open Access
- 8 May 2025
- Published by Wiley in Advanced Science
- Vol. 12 (27) , e2501552
Fn14 Controls the SIRT2‐Mediated Deacetylation of Slug to Inhibit the Metastasis of Epithelial Ovarian Cancer
Metastatic spread of cancer is the leading cause of death in patients with epithelial ovarian cancer (EOC), and elucidation of the molecular mechanisms underlying this process is a major focus of cancer research. Fibroblast growth factor‐inducible 14 (Fn14) has been shown to regulate wound repair, inflammation, angiogenesis, and chemoresistance, but its functional role in metastasis in EOC is still unknown. Here it is reported that Fn14 is identified as a cancer metastasis suppressor that inhibits the migratory and invasive potential of EOC cells by down‐regulating epithelial‐mesenchymal transition (EMT). Mechanistically, it is identified that Fn14 promotes acetylation‐dependent protein degradation of Slug, a key transcriptional factor associated with EMT. The deacetylase Sirtuin 2 (SIRT2) has been reported to be involved in the deacetylation of Slug protein to stabilize it and then prevent its degradation in the nucleus. The results showed that Fn14 alters the subcellular localization of (SIRT2) by interacting with SIRT2, leading to reduced SIRT2 shuttling into the nucleus and subsequently promoting the acetylated degradation of Slug. Collectively, the work has demonstrated for the first time that Fn14 inhibits EOC metastasis by regulating SIRT2‐mediated Slug deacetylation, providing a new perspective and method for the development of future novel therapeutic strategies for the treatment of EOC metastasis.
- 8 May 2025
- Published by Wiley in Advanced Science
- Vol. 12 (27) , e2501552
Open AccessFn14 Controls the SIRT2‐Mediated Deacetylation of Slug to Inhibit the Metastasis of Epithelial Ovarian Cancer
Metastatic spread of cancer is the leading cause of death in patients with epithelial ovarian cancer (EOC), and elucidation of the molecular mechanisms underlying this process is a major focus of cancer research. Fibroblast growth factor‐inducible 14 (Fn14) has been shown to regulate wound repair, inflammation, angiogenesis, and chemoresistance, but its functional role in metastasis in EOC is still unknown. Here it is reported that Fn14 is identified as a cancer metastasis suppressor that inhibits the migratory and invasive potential of EOC cells by down‐regulating epithelial‐mesenchymal transition (EMT). Mechanistically, it is identified that Fn14 promotes acetylation‐dependent protein degradation of Slug, a key transcriptional factor associated with EMT. The deacetylase Sirtuin 2 (SIRT2) has been reported to be involved in the deacetylation of Slug protein to stabilize it and then prevent its degradation in the nucleus. The results showed that Fn14 alters the subcellular localization of (SIRT2) by interacting with SIRT2, leading to reduced SIRT2 shuttling into the nucleus and subsequently promoting the acetylated degradation of Slug. Collectively, the work has demonstrated for the first time that Fn14 inhibits EOC metastasis by regulating SIRT2‐mediated Slug deacetylation, providing a new perspective and method for the development of future novel therapeutic strategies for the treatment of EOC metastasis.
- Open Access
- 12 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1551
A Novel Prognostic Signature of Mitophagy-Related E3 Ubiquitin Ligases in Breast Cancer
Mitophagy plays a critical role in maintaining mitochondrial quality and cellular homeostasis. But the specific contribution of mitophagy-related E3 ubiquitin ligases to prognoses remains largely unexplored. In this study, we identified a novel mitophagy-related E3 ubiquitin ligase prognostic signature using least absolute shrinkage and selector operator (LASSO) and multivariate Cox regression analyses in breast cancer. Based on median risk scores, patients were divided into high-risk and low-risk groups. Functional enrichment analyses were conducted to explore the biological differences between the two groups. Immune infiltration, drug sensitivity, and mitochondrial-related phenotypes were also analyzed to evaluate the clinical implications of the model. A four-gene signature (ARIH1, SIAH2, UBR5, and WWP2) was identified, and Kaplan–Meier analysis demonstrated that the high-risk group had significantly worse overall survival (OS). The high-risk patients exhibited disrupted mitochondrial metabolism and immune dysregulation with upregulated immune checkpoint molecules. Additionally, the high-risk group exhibited higher sensitivity to several drugs targeting the Akt/PI3K/mTORC1 signaling axis. Accompanying mitochondrial metabolic dysregulation, mtDNA stress was elevated, contributing to activation of the senescence-associated secretory phenotype (SASP) in the high-risk group. In conclusion, the identified signature provides a robust tool for risk stratification and offers insights into the interplay between mitophagy, immune modulation, and therapeutic responses for breast cancer.
- 12 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1551
Open AccessA Novel Prognostic Signature of Mitophagy-Related E3 Ubiquitin Ligases in Breast Cancer
Mitophagy plays a critical role in maintaining mitochondrial quality and cellular homeostasis. But the specific contribution of mitophagy-related E3 ubiquitin ligases to prognoses remains largely unexplored. In this study, we identified a novel mitophagy-related E3 ubiquitin ligase prognostic signature using least absolute shrinkage and selector operator (LASSO) and multivariate Cox regression analyses in breast cancer. Based on median risk scores, patients were divided into high-risk and low-risk groups. Functional enrichment analyses were conducted to explore the biological differences between the two groups. Immune infiltration, drug sensitivity, and mitochondrial-related phenotypes were also analyzed to evaluate the clinical implications of the model. A four-gene signature (ARIH1, SIAH2, UBR5, and WWP2) was identified, and Kaplan–Meier analysis demonstrated that the high-risk group had significantly worse overall survival (OS). The high-risk patients exhibited disrupted mitochondrial metabolism and immune dysregulation with upregulated immune checkpoint molecules. Additionally, the high-risk group exhibited higher sensitivity to several drugs targeting the Akt/PI3K/mTORC1 signaling axis. Accompanying mitochondrial metabolic dysregulation, mtDNA stress was elevated, contributing to activation of the senescence-associated secretory phenotype (SASP) in the high-risk group. In conclusion, the identified signature provides a robust tool for risk stratification and offers insights into the interplay between mitophagy, immune modulation, and therapeutic responses for breast cancer.
- Open Access
- 4 February 2025
- Published by MDPI AG in Preprints.org
A Novel Prognostic Signature of Mitophagy-Related E3 Ubiquitin Ligases in Breast Cancer
Mitophagy plays a critical role in maintaining mitochondrial quality and cellular homeostasis. But the specific contribution of mitophagy-related E3 ubiquitin ligases to prognosis remains largely unexplored. In this study, we identified a novel mitophagy-related E3 ubiquitin ligases prognostic signature using least absolute shrinkage and selector operator (LASSO) and multivariate Cox regression analyses in breast cancer. Based on median risk scores, patients were divided into high-risk and low-risk groups. Functional enrichment analyses were conducted to explore the biological differences between the two groups. Immune infiltration, drug sensitivity, and mitochondrial-related phenotypes were also analyzed to evaluate the clinical implications of the model. A four-gene signature (ARIH1, SIAH2, UBR5, and WWP2) was identified and Kaplan-Meier analysis demonstrated that the high-risk group had significantly worse overall survival (OS). High-risk patients exhibited disrupted mitochondrial metabolism and immune dysregulation with upregulated immune checkpoint molecules. Additionally, high-risk group exhibited higher sensitivity to several drugs targeting at Akt/PI3K/mTORC1 signaling axis. Accompanying mitochondrial metabolic dysregulation, mtDNA stress was elevated, contributing to the activation of senescence-associated secretory phenotype (SASP) in the high-risk group. In conclusion, the identified signature provides a robust tool for risk stratification and offers insights into the interplay between mitophagy, immune modulation, and therapeutic responses for breast cancer.
- 4 February 2025
- Published by MDPI AG in Preprints.org
Open AccessA Novel Prognostic Signature of Mitophagy-Related E3 Ubiquitin Ligases in Breast Cancer
Mitophagy plays a critical role in maintaining mitochondrial quality and cellular homeostasis. But the specific contribution of mitophagy-related E3 ubiquitin ligases to prognosis remains largely unexplored. In this study, we identified a novel mitophagy-related E3 ubiquitin ligases prognostic signature using least absolute shrinkage and selector operator (LASSO) and multivariate Cox regression analyses in breast cancer. Based on median risk scores, patients were divided into high-risk and low-risk groups. Functional enrichment analyses were conducted to explore the biological differences between the two groups. Immune infiltration, drug sensitivity, and mitochondrial-related phenotypes were also analyzed to evaluate the clinical implications of the model. A four-gene signature (ARIH1, SIAH2, UBR5, and WWP2) was identified and Kaplan-Meier analysis demonstrated that the high-risk group had significantly worse overall survival (OS). High-risk patients exhibited disrupted mitochondrial metabolism and immune dysregulation with upregulated immune checkpoint molecules. Additionally, high-risk group exhibited higher sensitivity to several drugs targeting at Akt/PI3K/mTORC1 signaling axis. Accompanying mitochondrial metabolic dysregulation, mtDNA stress was elevated, contributing to the activation of senescence-associated secretory phenotype (SASP) in the high-risk group. In conclusion, the identified signature provides a robust tool for risk stratification and offers insights into the interplay between mitophagy, immune modulation, and therapeutic responses for breast cancer.
- Open Access
- 27 November 2024
- Published by Walter de Gruyter GmbH in Global Medical Education
- Vol. 1 (1) , 53-62
Comparing the effects of blended learning and traditional instruction on “Medical Genetics and Embryonic Development” in undergraduate medical students: a randomized controlled trial
Objectives: The Shanghai Jiao Tong University School of Medicine is at the forefront of educational innovation to enhance student learning outcomes. Herein, this study aims to evaluate the effectiveness of blended learning compared to traditional on-site instruction in the “Medical Genetics and Embryonic Development” curriculum. Methods: A randomized trial was conducted involving 338 second-year clinical medicine students during the 2023–2024 academic year. The students were divided into two groups: one received blended learning and the other, on-site instruction. Students’ performance was evaluated using ongoing assessments together with mid-term and final exams. Results: Blended learning led to higher overall final grades, with no significant difference in quiz performance, but better exam scores compared to traditional learning. At the level of higher-order learning skills, students in the blended learning group performed better in karyotyping. However, the traditional on-site group slightly outperformed the blended learning group in case-based learning scores. Ultimately, approximately 92 % of students were satisfied with the blended learning course. Conclusions: Blended learning does show promise in improving the self-learning skill and overall learning outcomes of medical students. Future studies should focus on optimizing blended learning strategies and assessing their long-term impacts on clinical competencies.
- 27 November 2024
- Published by Walter de Gruyter GmbH in Global Medical Education
- Vol. 1 (1) , 53-62
Open AccessComparing the effects of blended learning and traditional instruction on “Medical Genetics and Embryonic Development” in undergraduate medical students: a randomized controlled trial
Objectives: The Shanghai Jiao Tong University School of Medicine is at the forefront of educational innovation to enhance student learning outcomes. Herein, this study aims to evaluate the effectiveness of blended learning compared to traditional on-site instruction in the “Medical Genetics and Embryonic Development” curriculum. Methods: A randomized trial was conducted involving 338 second-year clinical medicine students during the 2023–2024 academic year. The students were divided into two groups: one received blended learning and the other, on-site instruction. Students’ performance was evaluated using ongoing assessments together with mid-term and final exams. Results: Blended learning led to higher overall final grades, with no significant difference in quiz performance, but better exam scores compared to traditional learning. At the level of higher-order learning skills, students in the blended learning group performed better in karyotyping. However, the traditional on-site group slightly outperformed the blended learning group in case-based learning scores. Ultimately, approximately 92 % of students were satisfied with the blended learning course. Conclusions: Blended learning does show promise in improving the self-learning skill and overall learning outcomes of medical students. Future studies should focus on optimizing blended learning strategies and assessing their long-term impacts on clinical competencies.
- 23 December 2022
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (5) , 1441-1474
The multifaceted role of MUC1 in tumor therapy resistance
Tumor therapeutic resistances are frequently linked to the recurrence and poor prognosis of cancers and have been a key bottleneck in clinical tumor treatment. Mucin1 (MUC1), a heterodimeric transmembrane glycoprotein, exhibits abnormally overexpression in a variety of human tumors and has been confirmed to be related to the formation of therapeutic resistance. In this review, the multifaceted roles of MUC1 in tumor therapy resistance are summarized from aspects of pan-cancer principles shared among therapies and individual mechanisms dependent on different therapies. Concretely, the common mechanisms of therapy resistance across cancers include interfering with gene expression, promoting genome instability, modifying tumor microenvironment, enhancing cancer heterogeneity and stemness, and activating evasion and metastasis. Moreover, the individual mechanisms of therapy resistance in chemotherapy, radiotherapy, and biotherapy are introduced. Last but not least, MUC1-involved therapy resistance in different types of cancers and MUC1-related clinical trials are summarized. Graphical abstract
- 23 December 2022
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (5) , 1441-1474
The multifaceted role of MUC1 in tumor therapy resistance
Tumor therapeutic resistances are frequently linked to the recurrence and poor prognosis of cancers and have been a key bottleneck in clinical tumor treatment. Mucin1 (MUC1), a heterodimeric transmembrane glycoprotein, exhibits abnormally overexpression in a variety of human tumors and has been confirmed to be related to the formation of therapeutic resistance. In this review, the multifaceted roles of MUC1 in tumor therapy resistance are summarized from aspects of pan-cancer principles shared among therapies and individual mechanisms dependent on different therapies. Concretely, the common mechanisms of therapy resistance across cancers include interfering with gene expression, promoting genome instability, modifying tumor microenvironment, enhancing cancer heterogeneity and stemness, and activating evasion and metastasis. Moreover, the individual mechanisms of therapy resistance in chemotherapy, radiotherapy, and biotherapy are introduced. Last but not least, MUC1-involved therapy resistance in different types of cancers and MUC1-related clinical trials are summarized. Graphical abstract
- Open Access
- 26 October 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (10) , 1-16
The oncoprotein MUC1 facilitates breast cancer progression by promoting Pink1-dependent mitophagy via ATAD3A destabilization
Mitophagy is a vital process that controls mitochondria quality, dysregulation of which can promote cancer. Oncoprotein mucin 1 (MUC1) targets mitochondria to attenuate drug-induced apoptosis. However, little is known about whether and how MUC1 contributes to mitochondrial homeostasis in cancer cells. We identified a novel role of MUC1 in promoting mitophagy. Increased mitophagy is coupled with the translocation of MUC1 to mitochondria, where MUC1 interacts with and induces degradation of ATPase family AAA domain-containing 3A (ATAD3A), resulting in protection of PTEN-induced kinase 1 (Pink1) from ATAD3A-mediated cleavage. Interestingly, MUC1-induced mitophagy is associated with increased oncogenicity of cancer cells. Similarly, inhibition of mitophagy significantly suppresses MUC1-induced cancer cell activity in vitro and in vivo. Consistently, MUC1 and ATAD3A protein levels present an inverse relationship in tumor tissues of breast cancer patients. Our data validate that MUC1/ATAD3A/Pink1 axis-mediated mitophagy constitutes a novel mechanism for maintaining the malignancy of cancer cells, providing a novel therapeutic approach for MUC1-positive cancers.
- 26 October 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (10) , 1-16
Open AccessThe oncoprotein MUC1 facilitates breast cancer progression by promoting Pink1-dependent mitophagy via ATAD3A destabilization
Mitophagy is a vital process that controls mitochondria quality, dysregulation of which can promote cancer. Oncoprotein mucin 1 (MUC1) targets mitochondria to attenuate drug-induced apoptosis. However, little is known about whether and how MUC1 contributes to mitochondrial homeostasis in cancer cells. We identified a novel role of MUC1 in promoting mitophagy. Increased mitophagy is coupled with the translocation of MUC1 to mitochondria, where MUC1 interacts with and induces degradation of ATPase family AAA domain-containing 3A (ATAD3A), resulting in protection of PTEN-induced kinase 1 (Pink1) from ATAD3A-mediated cleavage. Interestingly, MUC1-induced mitophagy is associated with increased oncogenicity of cancer cells. Similarly, inhibition of mitophagy significantly suppresses MUC1-induced cancer cell activity in vitro and in vivo. Consistently, MUC1 and ATAD3A protein levels present an inverse relationship in tumor tissues of breast cancer patients. Our data validate that MUC1/ATAD3A/Pink1 axis-mediated mitophagy constitutes a novel mechanism for maintaining the malignancy of cancer cells, providing a novel therapeutic approach for MUC1-positive cancers.
- 23 April 2022
- Published by Springer Nature in Oncogene
- Vol. 41 (22) , 3064-3078
MUC1 triggers lineage plasticity of Her2 positive mammary tumors
Aberrant overexpression of mucin 1 (MUC1) and human epidermal growth factor receptor 2 (HER2) are often observed in breast cancer. However, the role of concomitant MUC1/HER2 in the development of breast cancer has not been fully illustrated. Following analysis of public microarray datasets that revealed a correlation between double MUC1 and HER2 positivity and a worse clinical outcome, we generated a mouse model overexpressing both Her2 and MUC1 cytoplasmic domain (MUC1-CD) to investigate their interaction in mammary carcinogenesis. Coexpression of Her2 and MUC1-CD conferred a growth advantage and promoted the development of spontaneous mammary tumors. Genomic analysis revealed that enforced expression of MUC1-CD and Her2 induces mammary tumor lineage plasticity, which is supported by gene reprogramming and mammary stem cell enrichment. Through gain- and loss-of-function strategies, we show that coexpression of Her2 and MUC1-CD is associated with downregulation of tricarboxylic acid (TCA) cycle genes in tumors. Importantly, the reduction in TCA cycle genes induced by MUC1-CD was found to be significantly connected to poor prognosis in HER2+ breast cancer patients. In addition, MUC1 augments the Her2 signaling pathway by inducing Her2/Egfr dimerization. These findings collectively demonstrate the vital role of MUC1-CD/Her2 collaboration in shaping the mammary tumor landscape and highlight the prognostic and therapeutic implications of MUC1 in patients with HER2+ breast cancer.
- 23 April 2022
- Published by Springer Nature in Oncogene
- Vol. 41 (22) , 3064-3078
MUC1 triggers lineage plasticity of Her2 positive mammary tumors
Aberrant overexpression of mucin 1 (MUC1) and human epidermal growth factor receptor 2 (HER2) are often observed in breast cancer. However, the role of concomitant MUC1/HER2 in the development of breast cancer has not been fully illustrated. Following analysis of public microarray datasets that revealed a correlation between double MUC1 and HER2 positivity and a worse clinical outcome, we generated a mouse model overexpressing both Her2 and MUC1 cytoplasmic domain (MUC1-CD) to investigate their interaction in mammary carcinogenesis. Coexpression of Her2 and MUC1-CD conferred a growth advantage and promoted the development of spontaneous mammary tumors. Genomic analysis revealed that enforced expression of MUC1-CD and Her2 induces mammary tumor lineage plasticity, which is supported by gene reprogramming and mammary stem cell enrichment. Through gain- and loss-of-function strategies, we show that coexpression of Her2 and MUC1-CD is associated with downregulation of tricarboxylic acid (TCA) cycle genes in tumors. Importantly, the reduction in TCA cycle genes induced by MUC1-CD was found to be significantly connected to poor prognosis in HER2+ breast cancer patients. In addition, MUC1 augments the Her2 signaling pathway by inducing Her2/Egfr dimerization. These findings collectively demonstrate the vital role of MUC1-CD/Her2 collaboration in shaping the mammary tumor landscape and highlight the prognostic and therapeutic implications of MUC1 in patients with HER2+ breast cancer.
- Open Access
- 18 August 2021
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 6 (1) , 1-4
WWP1 targeting MUC1 for ubiquitin-mediated lysosomal degradation to suppress carcinogenesis
- 18 August 2021
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 6 (1) , 1-4
Open AccessWWP1 targeting MUC1 for ubiquitin-mediated lysosomal degradation to suppress carcinogenesis